DiagnaMed Holdings Corp. (DMED) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 182.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.48
• Revenue Growth: N/A
• EPS Growth: 25.00%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 69
• Industry: Medical - Healthcare Information Services
• EPS (TTM): >-0.01
• Shares Outstanding: 80,052,640
• 10 Day Avg. Volume: 88,679
• 30 Day Avg. Volume: 182,382
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -10.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

DiagnaMed Holdings Corp. faces significant financial challenges, with zero revenue and negative equity overshadowing its operations. However, technical indicators suggest some short-term stability, and recent corporate events offer potential growth opportunities. The stock's valuation remains a concern due to a negative P/E ratio and lack of dividends, but strategic initiatives in hydrogen and collaborations provide some optimism.

DiagnaMed Holdings Corp. Business Overview & Revenue Model

Company Description

DiagnaMed Holdings Corp. (DMED) is a healthcare technology company that specializes in developing and commercializing diagnostic and monitoring solutions. The company operates in the sectors of medical technology and digital health, focusing on innovative products that enhance patient care and improve health outcomes. DiagnaMed's core offerings include advanced diagnostic tools, wearable health monitoring devices, and software platforms designed to integrate and analyze health data to provide actionable insights for healthcare providers and patients.

How the Company Makes Money

DiagnaMed Holdings Corp. generates revenue primarily through the sale of its diagnostic and monitoring solutions to healthcare providers, clinics, and hospitals. The company employs a revenue model that includes direct sales of its proprietary devices and software, as well as subscription-based services for data analytics and monitoring platforms. Key revenue streams also include licensing agreements for its technology and potential partnerships with other healthcare entities to co-develop and distribute innovative health solutions. Additionally, DiagnaMed may engage in strategic collaborations with research institutions and technology firms to enhance its product offerings and expand its market reach.

DiagnaMed Holdings Corp. Financial Statement Overview

Summary

DiagnaMed Holdings Corp. is struggling with zero revenue and substantial losses, leading to financial instability. The negative equity and cash flow performance highlight significant operational and strategic challenges. Immediate corrective actions are necessary to enhance financial health.

Income Statement

The company has consistently reported zero revenue across all periods, indicating challenges in generating sales. The net losses are significant, with no visible improvement in profitability. EBIT and EBITDA margins are negative, reflecting operational inefficiencies.

Balance Sheet

The equity has turned negative in the most recent TTM, indicating financial distress. The company has no debt, which is positive, but the negative stockholders' equity is a major concern. The equity ratio has deteriorated over time, showcasing declining financial stability.

Cash Flow

There is a negative trend in operating and free cash flows, demonstrating inefficient cash management. The company is facing challenges in converting operations into positive cash flow, with no growth in free cash flow. The cash flow situation further stresses financial instability.

Breakdown
Sep 2023	Sep 2022	Sep 2021
Income Statement		Total Revenue
0.00	0.00	0.00
	Gross Profit
0.00	―	―
	EBIT
-1.18M	-1.14M	580.48K
	EBITDA
-100.27K	0.00	0.00
	Net Income Common Stockholders
-1.28M	-1.13M	-1.95M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
606.96K	1.57M	2.36M
	Total Assets
662.27K	1.62M	2.39M
	Total Debt
0.00	0.00	0.00
	Net Debt
-606.96K	-1.57M	-2.36M
	Total Liabilities
426.38K	369.51K	150.24K
	Stockholders Equity
235.89K	1.25M	2.24M
Cash Flow		Free Cash Flow
-1.07M	-787.58K	-565.60K
	Operating Cash Flow
-1.07M	-787.58K	-565.60K
	Investing Cash Flow
0.00	0.00	34.07K
	Financing Cash Flow
104.25K	0.00	2.89M

DiagnaMed Holdings Corp. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.03
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:DMED, the sentiment is Positive. The current price of 0.03 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.10 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:DMED.

DiagnaMed Holdings Corp. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$5.31B	3.39	-40.42%	2.90%	18.11%	2.25%
QNC	51 Neutral	C$103.13M	―	-669.49%	―	―	―
DMED	35 Underperform		―		―	―	25.00%

DiagnaMed Holdings Corp. Corporate Events

DiagnaMed Secures $397,510 in Private Placement to Advance Tech Innovations

DiagnaMed Holdings Corp. has successfully closed its private placement, raising $397,510 through the issuance of 13,250,333 units. The funds will be used for the research, development, and commercialization of its hydrogen production and monitoring technology, as well as its BRAIN AGE® Brain Health AI Platform. This move is expected to bolster DiagnaMed’s position in the cleantech and life sciences sectors, potentially impacting its operational capabilities and market presence.

Spark’s Take on TSE:DMED Stock

According to Spark, TipRanks’ AI Analyst, TSE:DMED is a Underperform.

DiagnaMed Holdings Corp. faces significant financial challenges, with zero revenue and negative equity overshadowing its operations. However, technical indicators suggest some short-term stability, and recent corporate events offer potential growth opportunities. The stock’s valuation remains a concern due to a negative P/E ratio and lack of dividends, but strategic initiatives in hydrogen and collaborations provide some optimism.

To see Spark’s full report on TSE:DMED stock, click here.

DiagnaMed Secures FDA Orphan Drug Designation for ALS Treatment

DiagnaMed Holdings Corp. has been granted Orphan Drug Designation by the FDA for its use of molecular hydrogen in treating amyotrophic lateral sclerosis (ALS), marking a significant step forward in rare disease research. This designation not only highlights the potential of molecular hydrogen as a novel therapeutic option for ALS but also provides DiagnaMed with incentives such as tax credits and market exclusivity, enhancing its ability to accelerate development programs. Additionally, DiagnaMed has entered into a non-binding letter of intent with Revive Therapeutics to potentially acquire full rights to its intellectual property related to molecular hydrogen for ALS, aiming to advance treatment options for the ALS community.

DiagnaMed Announces $510,000 Private Placement to Boost Hydrogen and AI Initiatives

DiagnaMed Holdings Corp. has announced a private placement offering of up to $510,000, led by EMD Financial Inc., to support its research, development, and commercialization efforts in hydrogen production and its BRAIN AGE® Brain Health AI Platform. The offering will consist of units priced at $0.03 each, with each unit including one common share and one warrant, allowing the purchase of an additional share at $0.05 within 24 months. The funds raised will also be used for general corporate purposes, with the offering expected to close by March 31, 2025, pending necessary approvals.

DiagnaMed Collaborates with QIMC to Boost Quebec’s Hydrogen Production

DiagnaMed Holdings Corp. has announced its collaboration with Québec Innovative Materials Corp. to support Quebec’s hydrogen ambitions. Utilizing its proprietary electromagnetic heating technology, DiagnaMed aims to assist in the scalable production of natural hydrogen, aligning with Quebec’s emission reduction goals and potentially unlocking significant commercial value.

DiagnaMed Advances Commercialization of Hydrogen Production Technology

DiagnaMed Holdings Corp. has announced significant progress in the commercialization of its electromagnetic heating technology for hydrogen production. This advancement, developed by Dr. Qingwang Yuan, enhances the efficiency and cost-effectiveness of hydrogen extraction from petroleum and natural hydrogen fields. The company is integrating this technology into its existing systems and strengthening its partnership with Québec Innovative Materials Corp. to expand renewable energy applications and support the global shift to low-carbon energy. DiagnaMed is also pursuing business development and partnerships with petroleum and natural hydrogen exploration companies to leverage existing oil and gas infrastructure and accelerate natural hydrogen extraction.